<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03323164</url>
  </required_header>
  <id_info>
    <org_study_id>17-636E</org_study_id>
    <nct_id>NCT03323164</nct_id>
  </id_info>
  <brief_title>Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study</brief_title>
  <official_title>Changes in Peripapillary Blood Flow After Use of Anti-glaucoma Medications: A Prospective, Quantitative OCT Angiography Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wills Eye</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Optovue</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wills Eye</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the possible acute changes in peripapillary blood flow after&#xD;
      instillation of antiglaucoma medications in patients with primary open angle glaucoma (POAG),&#xD;
      normal tension glaucoma (NTG), or ocular hypertension (OHTN) using Optical Coherence&#xD;
      Tomography (OCT) angiography.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Reduction of intraocular pressure (IOP) with topical antihypertensive medications is the&#xD;
      mainstay of initial treatment in patients with OHTN, POAG, and NTG. Many patients, however,&#xD;
      continue to experience disease progression despite IOP reduction. Alternative mechanisms of&#xD;
      neurodegeneration, including vascular dysregulation and structural susceptibility of the&#xD;
      lamina cribrosa, have been proposed as important mechanisms in progression, particularly in&#xD;
      cases of NTG.&#xD;
&#xD;
      Prior studies have also found decreased calculated mean ocular perfusion with the use of&#xD;
      timolol compared to other antiglaucoma medications in patients with normal tension glaucoma.&#xD;
      Visual field deterioration has also been shown to be associated with systemic nocturnal&#xD;
      arterial hypotension in patients with NTG, POAG, and after anterior ischemic optic&#xD;
      neuropathy. The use of ophthalmic topical beta-blockers has been shown to lower nocturnal&#xD;
      diastolic blood pressure and heart rate. Thus, topical beta blockers are often avoided in the&#xD;
      treatment of NTG due to the potential risk of reduced optic nerve head perfusion&#xD;
&#xD;
      Studies evaluating optic nerve head (ONH) perfusion are limited. Earlier studies evaluated&#xD;
      indirect measurements, such as calculated mean ocular perfusion pressure or systemic&#xD;
      hypotension, as indications of optic nerve hypoperfusion. Direct measurements of ocular&#xD;
      perfusion have been attempted using retrobulbar color Doppler imaging, which demonstrated&#xD;
      decreased short posterior ciliary artery flow velocity in patients with glaucomatous visual&#xD;
      field progression. This technique, however, has yielded inconsistent results in other&#xD;
      studies, and is only capable of detecting gross changes to ocular blood flow.&#xD;
&#xD;
      Optical Coherence Tomography Angiography (OCTA) is a novel technique first introduced in 2014&#xD;
      using a custom swept-source OCT system.No studies currently exist to evaluate the effects of&#xD;
      antiglaucoma medications on peripapillary blood flow using OCTA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 10, 2017</start_date>
  <completion_date type="Actual">May 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Vessel Density in Treatment Groups Assessed by OCT Angiography</measure>
    <time_frame>5.5 hours (3 separate 30 minute OCT Angiography scans with 2 hour post-intervention in between each scan)</time_frame>
    <description>Percent change in peripapillary vessel density detected by OCT (optical coherence tomography) Angiography using spectrum amplitude decorrelation angiography (SSADA) algorithm with the use of topical brimonidine or timolol eye drops to lower eye pressure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Flow Index in Treatment Groups Assessed by OCT Angiography</measure>
    <time_frame>5.5 hours (3 separate 30 minute OCT Angiography scans with 2 hour post-intervention in between each scan)</time_frame>
    <description>Percent change in peripapillary Flow Index detected by OCT (optical coherence tomography) Angiography using spectrum amplitude decorrelation angiography (SSADA) algorithm with the use of topical brimonidine or timolol eye drops to lower eye pressure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of Percent Changes in Peripapillary Vessel Density in Treatment Groups Assessed by OCT Angiography</measure>
    <time_frame>5.5 hours (3 separate 30 minute OCT Angiography scans with 2 hour post-intervention in between each scan)</time_frame>
    <description>Comparison of the percent change in peripapillary vessel density detected by OCT (optical coherence tomography) Angiography using spectrum amplitude decorrelation angiography (SSADA) algorithm before and after the use of topical brimonidine or timolol eye drops to lower eye pressure. The Control groups represent the percent changes in vessel density after using artificial tears. The medicine groups (Brimonidine/Timolol) represents the percent changes in vessel density after using topical brimonidine or timolol drops to lower eye pressure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of Percent Changes in Peripapillary Flow Index in Treatment Groups Assessed by OCT Angiography</measure>
    <time_frame>5.5 hours (3 separate 30 minute OCT Angiography scans with 2 hour post-intervention in between each scan)</time_frame>
    <description>Comparison of the percent change in peripapillary flow index detected by OCT (optical coherence tomography) Angiography using spectrum amplitude decorrelation angiography (SSADA) algorithm before and after the use of topical brimonidine or timolol eye drops to lower eye pressure. The Control groups represent the percent changes in flow index after using artificial tears. The medicine groups (Brimonidine/Timolol) represents the percent changes in flow index after using topical brimonidine or timolol drops to lower eye pressure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of Percent Changes in Optic Nerve Head Vessel Density in Treatment Groups Assessed by OCT Angiography</measure>
    <time_frame>5.5 hours (3 separate 30 minute OCT Angiography scans with 2 hour post-intervention in between each scan)</time_frame>
    <description>Comparison of the percent change in optic nerve head vessel density detected by OCT (optical coherence tomography) Angiography using spectrum amplitude decorrelation angiography (SSADA) algorithm before and after the use of topical brimonidine or timolol eye drops to lower eye pressure. The Control groups represent the percent changes in vessel density after using artificial tears. The medicine groups (Brimonidine/Timolol) represents the percent changes in vessel density after using topical brimonidine or timolol drops to lower eye pressure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of Percent Changes in Optic Nerve Head Flow Index in Treatment Groups Assessed by OCT Angiography</measure>
    <time_frame>5.5 hours (3 separate 30 minute OCT Angiography scans with 2 hour post-intervention in between each scan)</time_frame>
    <description>Comparison of the percent change in Optic Nerve Head Flow Index detected by OCT (optical coherence tomography) Angiography using spectrum amplitude decorrelation angiography (SSADA) algorithm before and after the use of topical brimonidine or timolol eye drops to lower eye pressure. The Control groups represent the percent changes in flow index after using artificial tears. The medicine groups (Brimonidine/Timolol) represents the percent changes in flow index after using topical brimonidine or timolol drops to lower eye pressure.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Glaucoma; Drugs</condition>
  <condition>Normal Tension Glaucoma</condition>
  <condition>Primary Open-angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>Timolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Timolol maleate 0.5% ophthalmic solution Instillation of one drop in each eye, once.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brimonidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Brimonidine tartrate 0.2% Instillation of one drop in each eye, once.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol Maleate</intervention_name>
    <description>Instillation of one drop in each eye, one-time. Obtaining of OCT angiography scans after 2 hours of instillation.</description>
    <arm_group_label>Timolol</arm_group_label>
    <other_name>Timolol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brimonidine Tartrate</intervention_name>
    <description>Instillation of one drop in each eye, one-time. Obtaining of OCT angiography scans after 2 hours of instillation.</description>
    <arm_group_label>Brimonidine</arm_group_label>
    <other_name>Brimonidine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of ocular hypertension, primary open angle glaucoma, or normal tension&#xD;
             glaucoma in the study eye(s)&#xD;
&#xD;
          -  Age 18-90&#xD;
&#xD;
          -  Best corrected visual acuity of 20/60 or better&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current use of either brimonidine or timolol&#xD;
&#xD;
          -  Other disease, ophthalmic or systemic, that is likely to significantly affect the OCT&#xD;
             test in the study eye(s) including:&#xD;
&#xD;
               -  More than moderate grade cataract that significantly reducing OCTA scan signal&#xD;
                  level&#xD;
&#xD;
               -  Macular degeneration other than mild drusen or pigmentary changes&#xD;
&#xD;
               -  Diabetic retinopathy other than mild background non proliferative retinopathy&#xD;
&#xD;
               -  Prior or current macular edema&#xD;
&#xD;
               -  Prior laser treatment to the retina&#xD;
&#xD;
               -  Prior retinal detachment&#xD;
&#xD;
               -  Prior central serous retinopathy&#xD;
&#xD;
               -  Prior retinal vein or artery occlusion&#xD;
&#xD;
               -  Prior inflammatory retinopathy or choroidopathy&#xD;
&#xD;
               -  Keratoconus or other corneal ectasia&#xD;
&#xD;
               -  Corneal scarring in central 4 mm&#xD;
&#xD;
               -  Prior penetrating keratoplasty&#xD;
&#xD;
               -  Ischemic optic neuropathy&#xD;
&#xD;
               -  Dementia beyond early/mild memory loss&#xD;
&#xD;
               -  History of cerebrovascular accident&#xD;
&#xD;
               -  History of severe carotid stenosis&#xD;
&#xD;
               -  History of previous ocular surgery other than non-complicated cataract extraction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wills Eye Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glaucoma Research Center - Wills Eye Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 24, 2017</study_first_submitted>
  <study_first_submitted_qc>October 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2017</study_first_posted>
  <results_first_submitted>August 20, 2020</results_first_submitted>
  <results_first_submitted_qc>December 4, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 31, 2020</results_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wills Eye</investigator_affiliation>
    <investigator_full_name>Daniel Lee, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Low Tension Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 7, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT03323164/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Timolol</title>
          <description>Timolol maleate 0.5% ophthalmic solution Instillation of one drop in each eye, once.&#xD;
Timolol Maleate: Instillation of one drop in each eye, one-time. Obtaining optical coherence tomography (OCT) angiography scans after 2 hours of instillation.</description>
        </group>
        <group group_id="P2">
          <title>Brimonidine</title>
          <description>Brimonidine tartrate 0.2% Instillation of one drop in each eye, once.&#xD;
Brimonidine Tartrate: Instillation of one drop in each eye, one-time. Obtaining optical coherence tomography (OCT) angiography scans after 2 hours of instillation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Poor quality imaging/scans</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Timolol</title>
          <description>Timolol maleate 0.5% ophthalmic solution Instillation of one drop in each eye, once.&#xD;
Timolol Maleate: Instillation of one drop in each eye, one-time. Obtaining of OCT angiography scans after 2 hours of instillation.</description>
        </group>
        <group group_id="B2">
          <title>Brimonidine</title>
          <description>Brimonidine tartrate 0.2% Instillation of one drop in each eye, once.&#xD;
Brimonidine Tartrate: Instillation of one drop in each eye, one-time. Obtaining of OCT angiography scans after 2 hours of instillation.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glaucoma type</title>
          <description>Patients diagnosed with primary open angle glaucoma (POAG), normal tension glaucoma (NTG) or ocular hypertension (OHTN), with a best corrected visual acuity of at least 20/60 were invited to participate.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Vessel Density in Treatment Groups Assessed by OCT Angiography</title>
        <description>Percent change in peripapillary vessel density detected by OCT (optical coherence tomography) Angiography using spectrum amplitude decorrelation angiography (SSADA) algorithm with the use of topical brimonidine or timolol eye drops to lower eye pressure.</description>
        <time_frame>5.5 hours (3 separate 30 minute OCT Angiography scans with 2 hour post-intervention in between each scan)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Brimonidine Group</title>
            <description>POAG (primary open angle glaucoma), NTG (normal tension glaucoma) and OHTN (ocular hypertension) had OCTA (optical coherence tomography angiography) after receiving Brimonidine eye drops to lower eye pressure before .</description>
          </group>
          <group group_id="O2">
            <title>Timolol Group</title>
            <description>POAG (primary open angle glaucoma), NTG (normal tension glaucoma) and OHTN (ocular hypertension) had OCTA (optical coherence tomography angiography) after receiving Timolol eye drops to lower eye pressure before .</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Vessel Density in Treatment Groups Assessed by OCT Angiography</title>
          <description>Percent change in peripapillary vessel density detected by OCT (optical coherence tomography) Angiography using spectrum amplitude decorrelation angiography (SSADA) algorithm with the use of topical brimonidine or timolol eye drops to lower eye pressure.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="6.10"/>
                    <measurement group_id="O2" value="2.59" spread="6.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POAG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.96" spread="8.069"/>
                    <measurement group_id="O2" value="0.96" spread="6.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NTG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="6.67"/>
                    <measurement group_id="O2" value="4.12" spread="8.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OHTN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="4.48"/>
                    <measurement group_id="O2" value="2.37" spread="4.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Flow Index in Treatment Groups Assessed by OCT Angiography</title>
        <description>Percent change in peripapillary Flow Index detected by OCT (optical coherence tomography) Angiography using spectrum amplitude decorrelation angiography (SSADA) algorithm with the use of topical brimonidine or timolol eye drops to lower eye pressure.</description>
        <time_frame>5.5 hours (3 separate 30 minute OCT Angiography scans with 2 hour post-intervention in between each scan)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Brimonidine Group</title>
            <description>POAG (primary open angle glaucoma), NTG (normal tension glaucoma) and OHTN (ocular hypertension) had OCTA (optical coherence tomography angiography) after receiving Brimonidine eye drops to lower eye pressure before .</description>
          </group>
          <group group_id="O2">
            <title>Timolol Group</title>
            <description>POAG (primary open angle glaucoma), NTG (normal tension glaucoma) and OHTN (ocular hypertension) had OCTA (optical coherence tomography angiography) after receiving Timolol eye drops to lower eye pressure before .</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Flow Index in Treatment Groups Assessed by OCT Angiography</title>
          <description>Percent change in peripapillary Flow Index detected by OCT (optical coherence tomography) Angiography using spectrum amplitude decorrelation angiography (SSADA) algorithm with the use of topical brimonidine or timolol eye drops to lower eye pressure.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.23" spread="10.77"/>
                    <measurement group_id="O2" value="0.33" spread="5.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POAG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.55" spread="12.01"/>
                    <measurement group_id="O2" value="0.69" spread="7.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NTG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.87" spread="6.35"/>
                    <measurement group_id="O2" value="2.76" spread="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OHTN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="9.68"/>
                    <measurement group_id="O2" value="-2.92" spread="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Percent Changes in Peripapillary Vessel Density in Treatment Groups Assessed by OCT Angiography</title>
        <description>Comparison of the percent change in peripapillary vessel density detected by OCT (optical coherence tomography) Angiography using spectrum amplitude decorrelation angiography (SSADA) algorithm before and after the use of topical brimonidine or timolol eye drops to lower eye pressure. The Control groups represent the percent changes in vessel density after using artificial tears. The medicine groups (Brimonidine/Timolol) represents the percent changes in vessel density after using topical brimonidine or timolol drops to lower eye pressure.</description>
        <time_frame>5.5 hours (3 separate 30 minute OCT Angiography scans with 2 hour post-intervention in between each scan)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control B</title>
            <description>POAG (primary open angle glaucoma), NTG (normal tension glaucoma) and OHTN (ocular hypertension) had OCTA (optical coherence tomography angiography) before receiving Brimonidine eye drops to lower eye pressure before .</description>
          </group>
          <group group_id="O2">
            <title>Brimonidine</title>
            <description>POAG (primary open angle glaucoma), NTG (normal tension glaucoma) and OHTN (ocular hypertension) had OCTA (optical coherence tomography angiography) after receiving Brimonidine eye drops to lower eye pressure before .</description>
          </group>
          <group group_id="O3">
            <title>Control T</title>
            <description>POAG (primary open angle glaucoma), NTG (normal tension glaucoma) and OHTN (ocular hypertension) had OCTA (optical coherence tomography angiography) before receiving Timolol eye drops to lower eye pressure before .</description>
          </group>
          <group group_id="O4">
            <title>Timolol</title>
            <description>POAG (primary open angle glaucoma), NTG (normal tension glaucoma) and OHTN (ocular hypertension) had OCTA (optical coherence tomography angiography) after receiving Timolol eye drops to lower eye pressure before .</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Percent Changes in Peripapillary Vessel Density in Treatment Groups Assessed by OCT Angiography</title>
          <description>Comparison of the percent change in peripapillary vessel density detected by OCT (optical coherence tomography) Angiography using spectrum amplitude decorrelation angiography (SSADA) algorithm before and after the use of topical brimonidine or timolol eye drops to lower eye pressure. The Control groups represent the percent changes in vessel density after using artificial tears. The medicine groups (Brimonidine/Timolol) represents the percent changes in vessel density after using topical brimonidine or timolol drops to lower eye pressure.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" spread="6.68"/>
                    <measurement group_id="O2" value="-0.51" spread="6.10"/>
                    <measurement group_id="O3" value="-2.05" spread="3.90"/>
                    <measurement group_id="O4" value="2.59" spread="6.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POAG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.89" spread="10.73"/>
                    <measurement group_id="O2" value="-1.62" spread="9.15"/>
                    <measurement group_id="O3" value="-2.8" spread="4.64"/>
                    <measurement group_id="O4" value="0.96" spread="6.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NTG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" spread="5.59"/>
                    <measurement group_id="O2" value="-0.04" spread="6.67"/>
                    <measurement group_id="O3" value="-3.42" spread="4.01"/>
                    <measurement group_id="O4" value="4.12" spread="8.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OHTN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="4.89"/>
                    <measurement group_id="O2" value="-0.58" spread="4.48"/>
                    <measurement group_id="O3" value="0.34" spread="2.21"/>
                    <measurement group_id="O4" value="2.37" spread="4.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Percent Changes in Peripapillary Flow Index in Treatment Groups Assessed by OCT Angiography</title>
        <description>Comparison of the percent change in peripapillary flow index detected by OCT (optical coherence tomography) Angiography using spectrum amplitude decorrelation angiography (SSADA) algorithm before and after the use of topical brimonidine or timolol eye drops to lower eye pressure. The Control groups represent the percent changes in flow index after using artificial tears. The medicine groups (Brimonidine/Timolol) represents the percent changes in flow index after using topical brimonidine or timolol drops to lower eye pressure.</description>
        <time_frame>5.5 hours (3 separate 30 minute OCT Angiography scans with 2 hour post-intervention in between each scan)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control B</title>
            <description>POAG (primary open angle glaucoma), NTG (normal tension glaucoma) and OHTN (ocular hypertension) had OCTA (optical coherence tomography angiography) before receiving Brimonidine eye drops to lower eye pressure before .</description>
          </group>
          <group group_id="O2">
            <title>Brimonidine</title>
            <description>POAG (primary open angle glaucoma), NTG (normal tension glaucoma) and OHTN (ocular hypertension) had OCTA (optical coherence tomography angiography) after receiving Brimonidine eye drops to lower eye pressure before .</description>
          </group>
          <group group_id="O3">
            <title>Control T</title>
            <description>POAG (primary open angle glaucoma), NTG (normal tension glaucoma) and OHTN (ocular hypertension) had OCTA (optical coherence tomography angiography) before receiving Timolol eye drops to lower eye pressure before .</description>
          </group>
          <group group_id="O4">
            <title>Timolol</title>
            <description>POAG (primary open angle glaucoma), NTG (normal tension glaucoma) and OHTN (ocular hypertension) had OCTA (optical coherence tomography angiography) after receiving Timolol eye drops to lower eye pressure before .</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Percent Changes in Peripapillary Flow Index in Treatment Groups Assessed by OCT Angiography</title>
          <description>Comparison of the percent change in peripapillary flow index detected by OCT (optical coherence tomography) Angiography using spectrum amplitude decorrelation angiography (SSADA) algorithm before and after the use of topical brimonidine or timolol eye drops to lower eye pressure. The Control groups represent the percent changes in flow index after using artificial tears. The medicine groups (Brimonidine/Timolol) represents the percent changes in flow index after using topical brimonidine or timolol drops to lower eye pressure.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall group</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" spread="11.66"/>
                    <measurement group_id="O2" value="-5.23" spread="10.77"/>
                    <measurement group_id="O3" value="1.61" spread="11.10"/>
                    <measurement group_id="O4" value="0.33" spread="5.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POAG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.81" spread="15.26"/>
                    <measurement group_id="O2" value="-14.91" spread="12.45"/>
                    <measurement group_id="O3" value="-3.65" spread="5.33"/>
                    <measurement group_id="O4" value="0.69" spread="7.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NTG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="1.95"/>
                    <measurement group_id="O2" value="-4.87" spread="6.35"/>
                    <measurement group_id="O3" value="7.57" spread="16.31"/>
                    <measurement group_id="O4" value="2.76" spread="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OHTN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.89" spread="9.97"/>
                    <measurement group_id="O2" value="1.71" spread="9.68"/>
                    <measurement group_id="O3" value="-0.26" spread="2.95"/>
                    <measurement group_id="O4" value="-2.92" spread="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Percent Changes in Optic Nerve Head Vessel Density in Treatment Groups Assessed by OCT Angiography</title>
        <description>Comparison of the percent change in optic nerve head vessel density detected by OCT (optical coherence tomography) Angiography using spectrum amplitude decorrelation angiography (SSADA) algorithm before and after the use of topical brimonidine or timolol eye drops to lower eye pressure. The Control groups represent the percent changes in vessel density after using artificial tears. The medicine groups (Brimonidine/Timolol) represents the percent changes in vessel density after using topical brimonidine or timolol drops to lower eye pressure.</description>
        <time_frame>5.5 hours (3 separate 30 minute OCT Angiography scans with 2 hour post-intervention in between each scan)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control B</title>
            <description>POAG (primary open angle glaucoma), NTG (normal tension glaucoma) and OHTN (ocular hypertension) had OCTA (optical coherence tomography angiography) before receiving Brimonidine eye drops to lower eye pressure before .</description>
          </group>
          <group group_id="O2">
            <title>Brimonidine</title>
            <description>POAG (primary open angle glaucoma), NTG (normal tension glaucoma) and OHTN (ocular hypertension) had OCTA (optical coherence tomography angiography) after receiving Brimonidine eye drops to lower eye pressure before .</description>
          </group>
          <group group_id="O3">
            <title>Control T</title>
            <description>POAG (primary open angle glaucoma), NTG (normal tension glaucoma) and OHTN (ocular hypertension) had OCTA (optical coherence tomography angiography) before receiving Timolol eye drops to lower eye pressure before .</description>
          </group>
          <group group_id="O4">
            <title>Timolol</title>
            <description>POAG (primary open angle glaucoma), NTG (normal tension glaucoma) and OHTN (ocular hypertension) had OCTA (optical coherence tomography angiography) after receiving Timolol eye drops to lower eye pressure before .</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Percent Changes in Optic Nerve Head Vessel Density in Treatment Groups Assessed by OCT Angiography</title>
          <description>Comparison of the percent change in optic nerve head vessel density detected by OCT (optical coherence tomography) Angiography using spectrum amplitude decorrelation angiography (SSADA) algorithm before and after the use of topical brimonidine or timolol eye drops to lower eye pressure. The Control groups represent the percent changes in vessel density after using artificial tears. The medicine groups (Brimonidine/Timolol) represents the percent changes in vessel density after using topical brimonidine or timolol drops to lower eye pressure.</description>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="6.95"/>
                    <measurement group_id="O2" value="1.08" spread="6.67"/>
                    <measurement group_id="O3" value="0.32" spread="4.96"/>
                    <measurement group_id="O4" value="0.91" spread="5.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POAG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22" spread="7.87"/>
                    <measurement group_id="O2" value="-1.00" spread="6.02"/>
                    <measurement group_id="O3" value="-2.68" spread="4.37"/>
                    <measurement group_id="O4" value="2.65" spread="4.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NTG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.13" spread="7.03"/>
                    <measurement group_id="O2" value="2.44" spread="8.21"/>
                    <measurement group_id="O3" value="1.70" spread="6.30"/>
                    <measurement group_id="O4" value="0.16" spread="7.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OHTN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="7.50"/>
                    <measurement group_id="O2" value="1.65" spread="7.31"/>
                    <measurement group_id="O3" value="1.67" spread="2.66"/>
                    <measurement group_id="O4" value="0.08" spread="3.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Percent Changes in Optic Nerve Head Flow Index in Treatment Groups Assessed by OCT Angiography</title>
        <description>Comparison of the percent change in Optic Nerve Head Flow Index detected by OCT (optical coherence tomography) Angiography using spectrum amplitude decorrelation angiography (SSADA) algorithm before and after the use of topical brimonidine or timolol eye drops to lower eye pressure. The Control groups represent the percent changes in flow index after using artificial tears. The medicine groups (Brimonidine/Timolol) represents the percent changes in flow index after using topical brimonidine or timolol drops to lower eye pressure.</description>
        <time_frame>5.5 hours (3 separate 30 minute OCT Angiography scans with 2 hour post-intervention in between each scan)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control B</title>
            <description>POAG (primary open angle glaucoma), NTG (normal tension glaucoma) and OHTN (ocular hypertension) had OCTA (optical coherence tomography angiography) before receiving Brimonidine eye drops to lower eye pressure before .</description>
          </group>
          <group group_id="O2">
            <title>Brimonidine</title>
            <description>POAG (primary open angle glaucoma), NTG (normal tension glaucoma) and OHTN (ocular hypertension) had OCTA (optical coherence tomography angiography) after receiving Brimonidine eye drops to lower eye pressure before .</description>
          </group>
          <group group_id="O3">
            <title>Control T</title>
            <description>POAG (primary open angle glaucoma), NTG (normal tension glaucoma) and OHTN (ocular hypertension) had OCTA (optical coherence tomography angiography) before receiving Timolol eye drops to lower eye pressure before .</description>
          </group>
          <group group_id="O4">
            <title>Timolol</title>
            <description>POAG (primary open angle glaucoma), NTG (normal tension glaucoma) and OHTN (ocular hypertension) had OCTA (optical coherence tomography angiography) after receiving Timolol eye drops to lower eye pressure before .</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Percent Changes in Optic Nerve Head Flow Index in Treatment Groups Assessed by OCT Angiography</title>
          <description>Comparison of the percent change in Optic Nerve Head Flow Index detected by OCT (optical coherence tomography) Angiography using spectrum amplitude decorrelation angiography (SSADA) algorithm before and after the use of topical brimonidine or timolol eye drops to lower eye pressure. The Control groups represent the percent changes in flow index after using artificial tears. The medicine groups (Brimonidine/Timolol) represents the percent changes in flow index after using topical brimonidine or timolol drops to lower eye pressure.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.69" spread="12.08"/>
                    <measurement group_id="O2" value="-5.24" spread="10.05"/>
                    <measurement group_id="O3" value="1.96" spread="9.08"/>
                    <measurement group_id="O4" value="-0.69" spread="5.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POAG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.40" spread="14.22"/>
                    <measurement group_id="O2" value="-13.73" spread="11.02"/>
                    <measurement group_id="O3" value="-2.38" spread="3.64"/>
                    <measurement group_id="O4" value="-1.65" spread="7.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NTG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="3.42"/>
                    <measurement group_id="O2" value="-4.17" spread="5.77"/>
                    <measurement group_id="O3" value="6.21" spread="13.79"/>
                    <measurement group_id="O4" value="2.47" spread="2.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OHTN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.68" spread="13.18"/>
                    <measurement group_id="O2" value="0.55" spread="10.65"/>
                    <measurement group_id="O3" value="1.21" spread="2.61"/>
                    <measurement group_id="O4" value="-3.52" spread="4.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Timolol</title>
          <description>Timolol maleate 0.5% ophthalmic solution Instillation of one drop in each eye, once.&#xD;
Timolol Maleate: Instillation of one drop in each eye, one-time. Obtaining of OCT angiography scans after 2 hours of instillation.</description>
        </group>
        <group group_id="E2">
          <title>Brimonidine</title>
          <description>Brimonidine tartrate 0.2% Instillation of one drop in each eye, once.&#xD;
Brimonidine Tartrate: Instillation of one drop in each eye, one-time. Obtaining of OCT angiography scans after 2 hours of instillation.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limited sample size in this pilot study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Daniel Lee</name_or_title>
      <organization>Wills Eye Hospital</organization>
      <phone>12159283197</phone>
      <email>daniellee@willseye.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

